Sponsored: The Teva Biosimilars Trend Report

The Teva Biosimilars Trend Report: Perspectives from Managed Care, Providers & Employers.

In the second edition of The Teva Biosimilars Trend Report, it examines how payers, providers and employers navigate the evolving biosimilars market. Based on surveys and expert commentary conducted in 2024, the report highlights trends, barriers and opportunities affecting coverage and utilization.

Since 2015, biosimilars have saved the U.S. healthcare system an estimated $36 billion, including $11 billion in just 18 months from Humira (adalimumab) biosimilars. However, adoption remains uneven: oncology biosimilars exceed 80% market share, while others, such as Lucentis (ranibizumab), barely reach 1%. Slow uptake is driven by payer and PBM coverage decisions, provider reimbursement issues and regulatory challenges.

Educational efforts are improving physician confidence and reducing patient resistance. Looking ahead, biosimilar competition for high-cost drugs such as Stelara (ustekinumab), Eylea (aflibercept) and Prolia/Xgeva (denosumab) could yield substantial savings if access and reimbursement barriers are addressed. The report highlights the need for collaboration across decision-makers to fully embrace biosimilars’ clinical and economic potential.

Read the full report below: